Palatin Technologies (PTN)
(Delayed Data from AMEX)
$2.07 USD
-0.34 (-14.11%)
Updated May 15, 2024 04:00 PM ET
After-Market: $2.06 -0.01 (-0.48%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Palatin Technologies, Inc. [PTN]
Reports for Purchase
Showing records 181 - 196 ( 196 total )
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Top-line Results of Phase IIb FSD Study of BMT Expected in 4Q12
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
AZD2820 Discontinued; No Surprises; Focus Remains on FSD
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Hiccup, Likely Temporary, for AZD2820 Study; Target to $4.75
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F3Q12 Results; Expect Results from 2 Studies by Year End
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Positive FDA AdCom Vote for Lorcaserin; We See Positive Impact for Palatin
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Transferring Coverage; Rating, PT and Estimates Under Review
Provider: Roth Capital Partners, Inc.
Analyst: MARTIN J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F2Q Results, Completing Phase IIb Enrollment, Obesity Program Advancing
Provider: Roth Capital Partners, Inc.
Analyst: MOSKOWITZ D